Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Non-cash Items (2020 - 2023)

Historic Non-cash Items for Barinthus Biotherapeutics (BRNS) over the last 4 years, with Q3 2023 value amounting to $4.1 million.

  • Barinthus Biotherapeutics' Non-cash Items fell 5287.36% to $4.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was $4.1 million, marking a year-over-year decrease of 5287.36%. This contributed to the annual value of $7.1 million for FY2022, which is 5811.7% down from last year.
  • Latest data reveals that Barinthus Biotherapeutics reported Non-cash Items of $4.1 million as of Q3 2023, which was down 5287.36% from $6.5 million recorded in Q2 2023.
  • In the past 5 years, Barinthus Biotherapeutics' Non-cash Items ranged from a high of $19.8 million in Q2 2021 and a low of $4.1 million during Q3 2023
  • Moreover, its 4-year median value for Non-cash Items was $10.0 million (2020), whereas its average is $10.9 million.
  • Data for Barinthus Biotherapeutics' Non-cash Items shows a peak YoY increase of 16767.95% (in 2022) and a maximum YoY decrease of 5811.7% (in 2022) over the last 5 years.
  • Quarter analysis of 4 years shows Barinthus Biotherapeutics' Non-cash Items stood at $11.0 million in 2020, then skyrocketed by 53.82% to $17.0 million in 2021, then plummeted by 58.12% to $7.1 million in 2022, then crashed by 42.25% to $4.1 million in 2023.
  • Its last three reported values are $4.1 million in Q3 2023, $6.5 million for Q2 2023, and $9.0 million during Q1 2023.